Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

…, RA Dweik, E Israel, SP Peters, WW Busse… - American journal of …, 2010 - atsjournals.org
Rationale: The Severe Asthma Research Program cohort includes subjects with persistent
asthma who have undergone detailed phenotypic characterization. Previous univariate …

[HTML][HTML] Asthma: from bronchoconstriction to airways inflammation and remodeling

J Bousquet, PK Jeffery, WW Busse… - American journal of …, 2000 - atsjournals.org
BUSSE … Calhoun WJ, Jarjour NN, Gleich GJ, Stevens CA, Busse WWIncreased airway
inflammation with segmental versus aerosol antigen challenge. Am. Rev. … Nagata M …

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

…, HA Boushey, J Bousquet, WW Busse… - American journal of …, 2004 - atsjournals.org
For most patients, asthma is not controlled as defined by guidelines; whether this is achievable
has not been prospectively studied. A 1-year, randomized, stratified, double-blind, parallel…

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials …

…, LP Boulet, HA Boushey, WW Busse… - American journal of …, 2009 - atsjournals.org
Background: The assessment of asthma control is pivotal to the evaluation of treatment
response in individuals and in clinical trials. Previously, asthma control, severity, and …

[HTML][HTML] Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations

…, FD Martinez, ST Weiss, LK Williams… - Nature …, 2011 - ncbi.nlm.nih.gov
Asthma is a common disease with a complex risk architecture including both genetic and
environmental factors. We performed a meta-analysis of North American genome-wide …

[HTML][HTML] Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma

…, S Wenzel, KF Rabe, WW Busse… - New England journal …, 2018 - Mass Medical Soc
Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a …

…, K Ohta, M Lommatzsch, GT Ferguson, WW Busse… - The Lancet, 2016 - thelancet.com
Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …

Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program

…, SP Peters, WG Teague, DA Meyers, WW Busse… - Journal of Allergy and …, 2007 - Elsevier
BACKGROUND: Severe asthma causes the majority of asthma morbidity. Understanding
mechanisms that contribute to the development of severe disease is important. OBJECTIVE: …

Efficacy and safety of inhaled corticosteroids: new developments

PJ Barnes, S Pedersen, WW Busse - American journal of respiratory …, 1998 - atsjournals.org
Inhaled corticosteroids have revolutionized the treatment of asthma and have now become
the mainstay of therapy for patients with chronic disease (1). In a supplement to this journal …

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial

RA Pauwels, S Pedersen, WW Busse, WC Tan… - The Lancet, 2003 - thelancet.com
… Prof William W Busse, MD William W Busse … WW Busse contributed to study design,
reviewing the analysed data, and writing of the report. YZ Chen recruited patients, and supervised …